Ipsen in the World

Choose your location:

Choose a Language

Contact us
Discover who we are
Discover our therapeutic areas, where we continuously invest to innovate
We are dedicated to improving the lives of patients. Discover their patient stories
Welcome to our dedicated section for investors
Join our team!

Investors

As a global pharmaceutical company with a biotech mindset and a proven ability to provide new, life-changing therapies, Ipsen is a leading player in its core therapeutic areas.

2018 Registration Document

This registration document contains forward-looking statements about the Group’s targets and forecasts, including the Annual Financial Report. The registration document provides a comprehensive information about our company, its activities, financial information, HR, and legal information.

 

View audio version

 

Download

2019 half year financial report

 

 

 

 

 

 

Download

Documents

Contact

Phone: +44 (0)1 753 627 721 Phone: +33 (0)1 58 33 53 31

Contact us

Stock information

Share price and stock information, benchmark, orders, transactions: find out Ipsen share-related data.

Ipsen shares ADR program Shareholding structure Analyst coverage

Ipsen shares

  • Listed on: segment A of Euronext Paris
  • ISIN code: FR 0010259150
  • Mnemonic: IPN
  • FTSE classification: 486 – pharmaceuticals
  • Sectorial classification ICB: 4577 – pharmaceuticals
  • Nominal value: 1 euro
  • First trading day: December 7, 2005

ADR program

Ipsen established a sponsored level I American Depository Receipt (ADR) program in the United States in June 2010 with Deutsche Bank trust company Americas (Deutsche Bank).

  • Ticker: IPSEY
  • Structure: Sponsored Level I ADR
  • Exchange: OTC
  • Ratio (ORD:ADR): 1:4
  • ADR ISIN: US4626291060
  • ORD ISIN: FR0010259150

CONTACT DETAILS FOR ADR HOLDERS:

Deutsche Bank Shareholder Services
AST
Operations Center
6201 15th Avenue
Brooklyn, NY 11219
USA

Email:
Toll-free number: +1 (866) 706-0509
Direct Dial: +1 (718) 921-8137

The Company’s ADR program is sponsored by Deutsche Bank. As the depository bank Deutsche Bank performs the following roles for ADR holders:

  • Records and maintains the register of ADR holders
  • Is the stock transfer agent
  • Distributes dividends in U.S. dollars (if applicable)
  • Facilitates the proxy voting process and exercises the voting rights on behalf of ADR holders (if applicable)
  • Issues and cancels Ipsen ADSs (American Depository Shares)
  • Can distribute company circulars and Annual General Meeting documentation (if applicable)

For those holders who are not registered because their shares are held through a ‘Street name’ (nominee account), your nominee will receive company documents from time to time from Deutsche Bank to distribute to ADR holders. You need to make arrangements with your nominee if you wish to receive such documents and to be able to exercise your vote through the depositary bank at general meetings (if applicable).

Shareholding structure

Analyst coverage

  • Bank of America Merrill Lynch
 Sachin Jain
  • Barclays
 Emily Field
  • Berenberg
 Klara Fernandez
  • Bryan Garnier
 Eric Le Berrigaud
  • Credit Suisse
 Matthew Weston
  • Exane BNP Paribas
 Luisa Hector
  • Gilbert Dupont
 Guillaume Cuvillier
  • Goldman Sachs
  Diana Na
  • Jefferies
 Peter Welford
  • JP Morgan
 Richard Vosser
  • Midcap Partners
 Pierre Vaurice
  • Morgan Stanley
 Vincent Meunier
  • Oddo & Cie
 Christophe-Raphaël Ganet
  • Portzamparc
 Christophe Dombu
  • Societe Generale
 Delphine Le Louet
  • UBS
 Jack Scannell

Stock information

Research & Development pipeline

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules.

Learn more

We are focused on accelerating our sales growth while improving our profitability and cash flow generation, in order to further invest in business development to build an innovative and sustainable pipeline and to maintain the growth momentum of the business.


Aymeric Le Chatelier, CFO

Financial objectives and outlook

Our top-line sales growth and bottom-line performance in 2019 were better than they have ever been – and our pipeline is stronger than ever.

2020 financial objectives 2022 Financial outlook

2020 financial objectives

Full Year 2020 guidance

The Group has set the following financial targets for the current year, assuming no impact in 2020 of new somatostatin analog (SSA) generic entry:

  • Group sales growth year-on-year greater than +6.0% at constant currency; no impact of currency expected based on the current level of exchange rates.
  • Core Operating margin around 30.0% of net sales, excluding incremental investments in pipeline expansion initiatives.

 

  Initial guidance Updated guidance
Sales growth[1] > +13.0% > +14.0%
Core Operating margin (as a % of net sales) around 30.0% around 30.0%

 

1 Subsidiaries involved in the partnership between Ipsen and Schwabe Group are consolidated in accordance with the equity method starting 1 January, 2019. Year-on-year growth excluding foreign exchange impact established by recalculating net sales for the relevant period at the rate used for the previous period.

The 25th of March 2020, Ipsen provided an update related to the impact of the Covid-19 pandemic on its global business which is affected in varying degrees in the countries impacted by the coronavirus, with very different and evolving situations from one country to another.

Since the start of the health crisis, Ipsen has taken the necessary measures to ensure the safety of its employees around the world and to focus on business continuity so that it can provide patients with access to its medicines. As part of these preventive measures, and in line with local health authorities’ guidance, Ipsen has instituted a global travel ban as well as home office policies where appropriate. Ipsen has also paused in-person interactions with healthcare professionals in several markets where its field-based employees are working from home using technology to interact virtually with healthcare professionals (HCPs).

Ipsen sees a limited financial impact today given its resilient product portfolio comprised mostly of diversified treatments with highly-differentiating and long-acting formulations for critical chronic conditions. However, given the general economic slowdown, its performance year-to-date in China, reduced interactions with healthcare professionals and the uncertainty about the duration and scale of the health crisis, Ipsen has decided to suspend its 2020 financial guidance announced in February as it is not possible at this stage to quantify its impact on the Group’s financial statements. Further updates will be provided as the situation evolves.

2022 Financial outlook

The Group has updated its 2022 outlook taking into account the latest developments in its current business, mainly in the palovarotene development program:

  • Group net sales greater than €2.8 billion, assuming current level of exchange rates;
  • Core Operating margin greater than 28.0% of net sales

The outlook has been updated assuming no approval of additional meaningful products or indications (including no contribution from palovarotene), progressive entry of additional octreotide and lanreotide generics globally from 2021 and excluding the impact of incremental investments in pipeline expansion initiatives

[3] Assuming current level of exchange rates.

[4] Including both flare-up and chronic indications for FOP

Financial objectives

2019 - a record year for Ipsen

In 2019, Group sales grew by 14.8%, driven by Oncology which was up 20%.

In 2019, we saw double-digit growth in Europe and growth of almost 20% in North America.

Our Core Operating Income showed a 19% increase and our Core operating margin was 30.4% of sales, up 0.7 points.

Specialty Care sales growth was nearly 17%, reflecting strong performance across all major products and geographies.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2020